3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Breast Neoplasms
2
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Penile Squamous Cell Carcinoma (PSCC)
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Metastatic Urothelial Cancer
1
Melanoma
1
Lymphatic Metastasis
1
Gestational Trophoblastic Neoplasias (GTN)
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 10
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Advanced Solid Tumor
1
Interventions
Cyclophosphamide
7
venetoclax
6
Azacitidine
6
fludarabine
5
Cytarabine
4
Blood Specimen Collection
4
daratumumab
3
Lenalidomide
3
Daunorubicin
3
tislelizumab
2
fludarabine phosphate
2
Rituximab
2
Liquid Biopsy
2
Idarubicin
2
Gemtuzumab
2
Capecitabine
2
Busulfan
2
trastuzumab deruxtecan
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sugemalimab
1
sacituzumab govitecan
1
relugolix
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
ivosidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm, Residual
×
avelumab
×
Clear all
NCT04841148
2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
96 enrolled